Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Receivables: 2013-2019

Historic Change in Receivables for Theravance Biopharma (TBPH) over the last 7 years, with Dec 2019 value amounting to -$86,000.

  • Theravance Biopharma's Change in Receivables rose 96.42% to -$86,000 in Q4 2019 from the same period last year, while for Dec 2019 it was -$620,000, marking a year-over-year increase of 62.03%. This contributed to the annual value of -$620,000 for FY2019, which is 62.03% up from last year.
  • Theravance Biopharma's Change in Receivables amounted to -$86,000 in Q4 2019, which was up 40.69% from -$145,000 recorded in Q3 2019.
  • Over the past 5 years, Theravance Biopharma's Change in Receivables peaked at $1.5 million during Q2 2018, and registered a low of -$2.4 million during Q4 2018.
  • For the 3-year period, Theravance Biopharma's Change in Receivables averaged around -$53,833, with its median value being $13,500 (2017).
  • In the last 5 years, Theravance Biopharma's Change in Receivables tumbled by 4,368.18% in 2016 and then spiked by 1,192.92% in 2018.
  • Over the past 5 years, Theravance Biopharma's Change in Receivables (Quarterly) stood at $1.1 million in 2015, then plummeted by 119.93% to -$227,000 in 2016, then soared by 398.24% to $677,000 in 2017, then tumbled by 455.10% to -$2.4 million in 2018, then surged by 96.42% to -$86,000 in 2019.
  • Its last three reported values are -$86,000 in Q4 2019, -$145,000 for Q3 2019, and $118,000 during Q2 2019.